OBJECTIVE: Smoking is detrimental for Crohn's disease (CD), but beneficial for ulcerative colitis (UC). Earlier, we studied the effects of active and passive smoking in CD and UC patients from a university hospital. This study was conducted to assess the same effects in patients from a regional hospital. METHODS: A questionnaire focusing on cigarette smoke exposure was sent to 382 patients. Returned questionnaires (84%: 128 CD and 192 UC patients) were incorporated into a retrospective chart review about disease behaviour and received therapy. RESULTS: At diagnosis there were 52% (95% confidence interval: 43-60%) smokers among CD patients, 40% in a control population and 25% (95% confidence interval: 18-31%) among UC patients. There were less former (19 vs. 31%, P = 0.013) and never smokers at diagnosis (30 vs. 44%, P = 0.009) in CD than in UC. No detrimental effects of active or passive smoking on the course of CD were observed. UC patients who continued smoking after diagnosis needed less often two or more hospitalizations than never smokers (5 vs. 25%, P = 0.036). Otherwise no clear beneficial effects of active smoking on UC were observed. Passively smoking UC patients experienced more often extraintestinal manifestations (25 vs. 7%, P = 0.029) than nonpassive smokers. CONCLUSION: Also in a regional hospital inflammatory bowel disease population smoking is a risk factor to develop CD and protects against developing UC. We found no detrimental effects of smoking on the disease course of CD and no clear beneficial effects on the course of UC.
OBJECTIVE: Smoking is detrimental for Crohn's disease (CD), but beneficial for ulcerative colitis (UC). Earlier, we studied the effects of active and passive smoking in CD and UC patients from a university hospital. This study was conducted to assess the same effects in patients from a regional hospital. METHODS: A questionnaire focusing on cigarette smoke exposure was sent to 382 patients. Returned questionnaires (84%: 128 CD and 192 UC patients) were incorporated into a retrospective chart review about disease behaviour and received therapy. RESULTS: At diagnosis there were 52% (95% confidence interval: 43-60%) smokers among CDpatients, 40% in a control population and 25% (95% confidence interval: 18-31%) among UC patients. There were less former (19 vs. 31%, P = 0.013) and never smokers at diagnosis (30 vs. 44%, P = 0.009) in CD than in UC. No detrimental effects of active or passive smoking on the course of CD were observed. UC patients who continued smoking after diagnosis needed less often two or more hospitalizations than never smokers (5 vs. 25%, P = 0.036). Otherwise no clear beneficial effects of active smoking on UC were observed. Passively smoking UC patients experienced more often extraintestinal manifestations (25 vs. 7%, P = 0.029) than nonpassive smokers. CONCLUSION: Also in a regional hospital inflammatory bowel disease population smoking is a risk factor to develop CD and protects against developing UC. We found no detrimental effects of smoking on the disease course of CD and no clear beneficial effects on the course of UC.
Authors: Tiago Nunes; Maria Josefina Etchevers; Valle García-Sánchez; Daniel Ginard; Eva Martí; Manuel Barreiro-de Acosta; Fernando Gomollón; Maite Arroyo; Guillermo Bastida; Benito Gonzalez; David Monfort; Esther García-Planella; Carolina Figueroa; Julián Panés; Miquel Sans Journal: Am J Gastroenterol Date: 2016-02-09 Impact factor: 10.864
Authors: Dalin Li; Talin Haritunians; Carol Landers; Alka A Potdar; Shaohong Yang; Hailiang Huang; L Philip Schumm; Mark Daly; Stephan R Targan; Dermot P B McGovern Journal: Inflamm Bowel Dis Date: 2018-10-12 Impact factor: 5.325
Authors: Hilary K Brown; Andrew Wilton; Ning Liu; Joel G Ray; Cindy-Lee Dennis; Simone N Vigod Journal: Clin Epidemiol Date: 2021-12-06 Impact factor: 4.790
Authors: Joana Torres; Flavio Caprioli; Konstantinos H Katsanos; Triana Lobatón; Dejan Micic; Marco Zerôncio; Gert Van Assche; James C Lee; James O Lindsay; David T Rubin; Remo Panaccione; Jean-Frédéric Colombel Journal: J Crohns Colitis Date: 2016-06-09 Impact factor: 9.071